QURE
uniQure N.V.
November 2, 2026 · pre-market
- Rarity
- 2.61
- Peak move
- +22.43%
- Float cap
- $1.4B
uniQure N.V. is a gene therapy company developing single treatments with potentially curative results for patients with rare and other devastating diseases. It is advancing clinical candidates for Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis caused by SOD1 mutations. These investigational therapies are intended for patients with serious, rare conditions and are not yet approved for commercial sale.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.